CNR Institutional Research Information System

EVANGELISTI, CAMILLA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 293
AS - Asia 68
EU - Europa 18
SA - Sud America 1
Totale 380
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 293
SG - Singapore 67
FI - Finlandia 8
IT - Italia 5
ES - Italia 2
AE - Emirati Arabi Uniti 1
CO - Colombia 1
DE - Germania 1
FR - Francia 1
SE - Svezia 1
Totale 380
Salva come PNG Salva come JPEG
Città #
Santa Clara 275
Singapore 50
Helsinki 8
Padova 2
Ashburn 1
Falkenstein 1
Forest City 1
Melegnano 1
Phoenix 1
Totale 340
Salva come PNG Salva come JPEG
Nome #
Lamin A and Prelamin a Counteract Migration of Osteosarcoma Cells 15
Targeting Wnt/beta-catenin and PI3K/Akt/mTOR pathways in T-cell acute lymphoblastic leukemia 13
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Cascade Inhibitors: How Mutations Can Result in Therapy Resistance and How to Overcome Resistance. 11
Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. 11
Synergistic cytotoxic effects of bortezomib and CK2 inhibitor CX-4945 in acute lymphoblastic leukemia: turning off the prosurvival ER chaperone BIP/Grp78 and turning on the pro-apoptotic NF-?B. 10
The role played by wnt/beta-catenin signaling pathway in acute lymphoblastic leukemia 10
Elevated TGF beta 2 serum levels in Emery-Dreifuss Muscular Dystrophy: Implications for myocyte and tenocyte differentiation and fibrogenic processes 10
Targeting the cancer initiating cell: The ultimate target for cancer therapy 10
Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: Eliminating activity by targeting at different levels. 10
Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. 10
The emerging multiple roles of nuclear Akt. 10
Modulation of TGFbeta 2 levels by lamin A in U2-OS osteoblast-like cells: understanding the osteolytic process triggered by altered lamins 10
B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients? 10
Increased NGAL (Lnc2) expression after chemotherapeutic drug treatment 10
Therapeutic potential of targeting sphingosine kinases and sphingosine 1-phosphate in hematological malignancies. 9
Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway 9
Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells. 9
Potential therapeutic effects of the mtor inhibitors for preventing ageing and progeria-related disorders. 9
The Cutting Edge: The Role of mTOR Signaling in Laminopathies 9
Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting 9
Targeting phosphatidylinositol 3-kinase signaling in acute myelogenous leukemia 9
Crosstalks of GSK3 signaling with the mTOR network and effects on targeted therapy of cancer. 9
Therapeutic targeting of CK2 in acute and chronic leukemias 9
Advances in targeting signal transduction pathways. 8
PI3K pan-inhibition impairs more efficiently proliferation and survival of T-cell acute lymphoblastic leukemia cell lines when compared to isoform-selective PI3K inhibitors 8
Targeting the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling network in cancer stem cells. 8
Therapeutic potential of targeting mTOR in T-cell acute lymphoblastic leukemia (Review) 8
Cytotoxic activity of the casein kinase 2 inhibitor CX-4945 against T-cell acute lymphoblastic leukemia: Targeting the unfolded protein response signaling 8
Targeting the liver kinase B1/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies. 8
GSK-3: a multifaceted player in acute leukemias 8
The unfolded protein response: A novel therapeutic target in acute leukemias 8
Therapeutic targeting of mTOR in T-cell acute lymphoblastic leukemia: An update 8
New advances in targeting aberrant signaling pathways in T-cell acute lymphoblastic leukemia 8
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mtor cascades which alter therapy response 8
Targeting the translational apparatus to improve leukemia therapy: Roles of the PI3K/PTEN/Akt/mTOR pathway 7
Phosphatidylinositol 3-kinase inhibition potentiates glucocorticoid response in B-cell acute lymphoblastic leukemia 7
Current treatment strategies for inhibiting mTOR in cancer 7
Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; Indications for novel therapeutics 7
Autophagy in acute leukemias: A double-edged sword with important therapeutic implications 7
PI3K isoform inhibition associated with anti Bcr-Abl drugs shows in vitro increased anti-leukemic activity in Philadelphia chromosome-positive B-acute lymphoblastic leukemia cell lines 7
Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. 7
GSK-3beta: A key regulator of breast cancer drug resistance (Comment on: Sokolosky M, et al. Cell Cycle 2014; 13:820-33;) 7
Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia 6
DGKzeta is degraded through the cytoplasmic ubiquitin-proteasome system under excitotoxic conditions, which causes neuronal apoptosis because of aberrant cell cycle reentry. 6
Totale 387
Salva come PNG Salva come JPEG
Categoria #
all - tutte 1.495
article - articoli 1.495
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.990
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2023/20242 0 0 0 0 0 0 0 0 1 0 0 1
2024/2025385 6 4 56 27 233 56 3 0 0 0 0 0
Totale 387